MammaTyper Test Able to Identify Women at Low Risk of Breast Cancer Spreading, Studies Show

MammaTyper Test Able to Identify Women at Low Risk of Breast Cancer Spreading, Studies Show
BioNTech Diagnostics' MammaTyper test lets doctors determine the type of breast cancer a woman has and identify patients at low risk of having their cancer spread. The company discussed the diagnostic test's effectiveness at the Breast Cancer Symposium in San Antonio in December 2017. MammaTyper measures levels of several breast cancer biomarkers in messenger RNA, a molecule that is an intermediary between a gene and a protein. The biomarkers are estrogen receptor, or ER; progesterone receptor, or PR; human epidermal growth factor receptor 2, or HER2; and a cell multiplication signpost known as Ki-67. The levels of these proteins determine which one of five types of cancer a patient has. The categories are luminal A-like; luminal B-like HER2 negative; luminal B-like HER2 positive; HER2 positive non-luminal; and triple negative ductal. These categories help doctors predict the course of the disease and select treatments. A clinical trial (NCT02244580) looked at whether MammaTyper could do a better job than standard analysis of predicting which patients were at low risk of their breast cancer progressing or recurring. Standard analysis involves using an online tool to assess levels of protein markers in tissue samples. The yardstick that doctors use to predict cancer returning is patients' Oncotype DX Recurrence Scores. Researchers titled the study they generated
Subscribe or to access all post and page content.

2 comments

  1. Anonymous says:

    magnificent points altogether, you just gained a new reader. What would you recommend in regards to your post that you made some days ago? Any positive?

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.